Array BioPharma Inc. (NASDAQ:ARRY) Files An 8-K Financial Statements and ExhibitsItem 9.01
(d)Exhibits
| Exhibit No. | Description |
| 99.1 |
Press release announcing the submission of New Drug Applications to the Food and Drug Administration for binimetinib and encorafenib in patients with advanced BRAF-mutant melanoma |
ARRAY BIOPHARMA INC ExhibitEX-99.1 2 v470295_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Array BioPharma Submits New Drug Applications To FDA For Binimetinib And Encorafenib In Advanced MelanomaBOULDER,…To view the full exhibit click here
About Array BioPharma Inc. (NASDAQ:ARRY)
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382. Array BioPharma Inc. (NASDAQ:ARRY) Recent Trading Information
Array BioPharma Inc. (NASDAQ:ARRY) closed its last trading session up +0.33 at 8.70 with 1,429,908 shares trading hands.